Nao-Xue-Shu Oral Liquid Improves Aphasia of Mixed Stroke
Table 3
Changes in hemorheology between before and after the additional treatments in the treatment and control groups.
WBVLS (mPa·s)
WBVHS (mPa·s)
PV (mPa·s)
ESRE value
Fibrinogen (g/L)
EA index
Treatment group ()
Before
18.83 ± 4.36
3.82 ± 0.57
1.81 ± 0.52
68.27 ± 39.25
4.82 ± 1.25
4.72 ± 0.81
Week 2
17.96 ± 4.09
3.72 ± 0.35
1.68 ± 0.32
59.19 ± 41.62
4.19 ± 1.02
3.96 ± 0.63
Week 4
16.65 ± 3.7
3.53 ± 0.3
1.47 ± 0.4
53.56 ± 40.6
3.47 ± 0.7
3.25 ± 0.5
Control group ()
Before
18.74 ± 5.05
3.82 ± 0.35
1.81 ± 0.37
67.82 ± 41.25
4.79 ± 1.46
4.70 ± 0.65
Week 2
18.38 ± 5.23
3.79 ± 0.62
1.76 ± 0.42
64.99 ± 39.02
4.02 ± 1.33
4.65 ± 0.92
Week 4
17.99 ± 4.59
3.77 ± 0.53
1.71 ± 0.38
63.47 ± 44.72
3.95 ± 1.49
3.97 ± 0.59
Note. WBVLS: whole blood viscosity low shear; WBVHS: whole blood viscosity high shear; PV: plasma viscosity; ESRE value: erythrocyte sedimentation rate equation value; and EA index: erythrocyte aggregation index. and compared with before for the same group; compared with control group at the same duration.
